# OnCo record nct03157128 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03157128/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03157128", "NCT03157128" ;
  schema:name "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET"@en ;
  schema:alternateName "LIBRETTO-001"@en ;
  schema:description "A phase 1/2 trial of Selpercatinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03157128/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03157128>, <https://doi.org/10.1056/NEJMoa2005653>, <https://www.nice.org.uk/guidance/ta1042> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2017-05-02" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/ret-fusion-nsclc/>, <https://onco.cc/cancers/medullary-thyroid-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/libretto-431/>, <https://onco.cc/trials/arrow-thyroid/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/>, <https://onco.cc/key-papers/paper-nct03157128-j-clin-oncol-2024-update/> .